ORYZON receives “Intention to grant” communication for patent relating to the use of vafid... 11/09/2024 Healthcare Innovative drugs The intention to grant is a formal communication from the EPO in which it indicates that the patent application has... Partners - Oryzon Genomics
Biological Sex Differences in Health: Challenges and Opportunities for Personalised Medici... 10/09/2024 Healthcare Personalized medicine Biological sex should be considered as a variable in all health-related biomedical research. Partners - GENESIS Biomed
IBRILATAZAR (ABTL0812) from AbilityPharma increases chemotherapy efectiveness by 40% in pa... 09/09/2024 Healthcare Innovative drugs Ibrilatazar is an oral drug with a novel mechanism of acton that induces autophagy through the inducton of ER-stress and... Partners - Ability Pharmaceuticals
ORYZON announces first patient dosed in an Investigator-initiated Phase Ib study of iadade... 09/09/2024 Healthcare Innovative drugs Exploring the triple combination with venetoclax and azacitidine. Study sponsored by Oregon Health & Science University... Partners - Oryzon Genomics
ORYZON continues to strengthen its patent portfolio for vafidemstat with additional “Decis... 03/09/2024 Healthcare Rare diseases Innovative drugs In Australia, Malaysia and Mexico. Partners - Oryzon Genomics
The Organ-on-Chip Revolution: A Technology Enhancing Drug Development 04/09/2024 Healthcare Access to innovation Organ-on-Chip (OOC) technologies are an innovative approach that replicates human organ structures and functions on... Partners - BeCytes Biotechnologies
NLRP3: From Scientific Curiosity to Therapeutic Efficacy 04/09/2024 Healthcare Personalized medicine Advanced therapies Joaquín Gómez Moya, executive president of Viva in Vitro, explains in this forum the important role of the NLRP3... Partners - VIVA IN VITRO
BCN HEALTH publishes study on productivity losses due to lung cancer in Spain 30/08/2024 Healthcare Lung cancer was responsible for 69,225 deaths in the ten years of the study. Partners - BCN Health
Vaxdyn awarded €14.5 Million from the EIC Accelerator to Fund the Clinical Phase of Its Va... 02/09/2024 Healthcare Access to innovation Innovative drugs Antibiotic resistance The European Commission is committed to combating antibiotic resistance through vaccines, selecting Vaxdyn's competitive... Partners - Vaxdyn
III TEAM-PRRC ANNUAL SUMMIT IPV HOTEL Málaga, Carretera A7. Km. 1018, 29640 Fuengirola, España Del 17/10/2024 to 18/10/2024 Healthcare
